(TheNewswire)
L ondon, Ontario - TheNewswire - June 1, 2021 -Sernova Corp. (TSXV:SVA) (OTC:SEOVF ) (FSE/XETRA:PSH ), a leading clinical-stage regenerativemedicine therapeutics company, is pleased to announce that leadprincipal investigator Dr. Piotr Witkowski and the Clinical TrialInvestigator Team for its US Phase I/II Type 1 Diabetes clinical trialwill present data and observations from the ongoing study in apresentation at the upcoming American Transplant Congress (ATC)Virtual Connect to be held June 4 - 9, 2021.
The live presentation entitled “ Islet Allotransplantation Into the Pre-Vascularized Sernova CellPouch TM Device - Preliminary Resultsfrom University of Chicago ” will be available to conferenceattendees on Saturday, June 5, 2021 at 6:30pm ET.
ABOUT SERNOVA’S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel,proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device upon implantation is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins and hormones as required to treat disease. The CellPouch, along with therapeutic cells, has been shown to providelong-term safety and efficacy in small and large animal models ofdiabetes and has been proven to provide a biologically compatibleenvironment for insulin-producing cells in humans.
ABOUT SERNOVA
Sernova is developing regenerative medicine therapeutic technologiesusing a medical device and immune protected therapeutic cells (i.e.human donor cells, corrected human cells and stem cell-derived cells)to improve the treatment and quality of life of people with chronicmetabolic diseases such as insulin-dependent diabetes, blood disordersincluding hemophilia, and other diseases treated through replacementof proteins or hormones missing or in short supply within the body.For more information, please visit www.sernova.com .
ABOUT THE AMERICAN TRANSPLANTCONGRESS
The American Transplant Congress (ATC) is the joint annual Congress ofthe American Society ofTransplant Surgeons (ASTS) and the American Society ofTransplantation (AST). ATC provides a forum for exchange of newscientific and clinical information relevant to solid organ and tissuetransplantation and brings together transplant physicians, scientists,nurses, organ procurement personnel, pharmacists, allied healthprofessionals, and other transplant professionals. The educationalofferings provide attendees the opportunity to learn cutting-edgeadvances in research and promotes the exchange of ideas and practicein the field of solid organ and tissue transplantation. ATC is anannual Congress that welcomes over 5,000 transplant professionals topresent cutting-edge science that covers all organ types and offersinsight into the future of the field and patient care.
ABOUT ATC 2021 VIRTUAL CONNECT
ATC 2021 Virtual Connect , is the ATC’snew, enhanced virtual meeting experience for transplantationprofessionals taking place June 4-9, 2021. This year’s all-virtualformat will feature a robust program of new scientific and clinicalinformation, discussions around care and management, andsocioeconomic, ethical, and regulatory issues relevant to organ andtissue transplantation. This year’s program will also feature newCOVID-19 content pertinent to the field of transplantation.
FOR FURTHER INFORMATION, PLEASECONTACT:
Investor Relations
Sernova Corp.
Tel: (519) 858-5126
Investorrelations@sernova.com
www.sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are notrecitations of historical facts, may constitute “forward-lookingstatements” that involve various risks, uncertainties, andassumptions, including, without limitation, statements regarding theprospects, plans, and objectives of the company. Wherever possible,but not always, words such as "expects", "plans","anticipates", "believes", "intends","estimates", "projects", "potential for"and similar expressions, or that events or conditions"will", "would", "may","could" or "should" occur are used to identifyforward-looking statements. These statements reflect management’sbeliefs with respect to future events and are based on informationcurrently available to management on the date such statements weremade. Many factors could cause Sernova’s actual results,performances or achievements to not be as anticipated, estimated orintended or to differ materially from those expressed or implied bythe forward-looking statements contained in this news release. Many ofthe factors are beyond our control, including those caused by, relatedto, or impacted by the novel coronavirus pandemic. Investors shouldconsult the company’s quarterly and annual filings available onwww.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.